A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer-Reference-Cited by-同舟云学术

A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer

Published:2017-11-21 Issue:1 Volume:5 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Dillon Patrick M.^ORCID,Petroni Gina R.,Smolkin Mark E.,Brenin David R.,Chianese-Bullock Kimberly A.,Smith Kelly T.,Olson Walter C.,Fanous Ibrahim S.,Nail Carmel J.,Brenin Christiana M.,Hall Emily H.,Slingluff Craig L.

Funder

National Cancer Institute

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/s40425-017-0295-5.pdf

Reference70 articles.

1. Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol. 2016;34(21):2460–7.

2. Emens L, Adams S, Loi S, Schmid P, Schneeweiss A, Rugo H et al. A phase III randomized trial of atezolizumab in combination with nab-paclitaxel as first line therapy for patients with metastatic triple-negative breast cancer (mTNBC). Cancer res 76[4s]. 2-15-2016. Ref Type: Abstract.

3. Antonilli M, Rahimi H, Visconti V, Napoletano C, Ruscito I, Zizzari IG, et al. Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: clinical and immunological data of a phase I/II clinical trial. Int J Oncol. 2016;48(4):1369–78.

4. Disis ML, Gad E, Herendeen DR, Lai VP, Park KH, Cecil DL, et al. A multiantigen vaccine targeting neu, IGFBP-2, and IGF-IR prevents tumor progression in mice with preinvasive breast disease. Cancer Prev Res (Phila). 2013;6(12):1273–82.

5. Mittendorf EA, Ardavanis A, Litton JK, Shumway NM, Hale DF, Murray JL, et al. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence. Oncotarget. 2016;7(40):66192–201.

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanoparticle-Mediated Immunotherapy in Triple-Negative Breast Cancer;ACS Biomaterials Science & Engineering;2024-05-30

2. Breast Cancer Immune Landscape: Interplay Between Systemic and Local Immunity;Advanced Biology;2024-05-10

3. Nanotechnology-mediated delivery of resveratrol as promising strategy to improve therapeutic efficacy in triple negative breast cancer (TNBC): progress and promises;Expert Opinion on Drug Delivery;2024-02

4. Toll-like receptor agonists as cancer vaccine adjuvants;Human Vaccines & Immunotherapeutics;2023-12-28

5. Immunoinformatics-Based Identification of the Conserved Immunogenic Peptides Targeting of Zika Virus Precursor Membrane Protein;Viral Immunology;2023-10-01